Cyprumed

Executive Summary

Cyprumed is an Austrian drug delivery company founded in 2018, specializing in non-invasive oral administration of biologics and challenging small molecules. Its proprietary platform enables the transformation of injectable peptides, including GLP-1 agonists, and BCS Class IV drugs such as PROTACs into oral tablet formulations. By addressing a critical unmet need in patient compliance and convenience, Cyprumed's technology has the potential to unlock large markets currently dominated by injectables, particularly in metabolic diseases and oncology. The company collaborates with major pharmaceutical partners, leveraging its expertise to co-develop oral versions of high-value therapeutics. With a focus on the rapidly growing oral peptide market, Cyprumed is well-positioned to capture significant value. The company has made progress in validating its platform through preclinical and early clinical studies, though specific timeline details are limited. Key upcoming catalysts include potential partnership announcements for its oral GLP-1 agonist program, progress toward an IND filing for an oral PROTAC candidate, and a Series A financing round to support pipeline advancement. As a private entity, Cyprumed remains relatively under the radar, but its platform technology and partnerships suggest meaningful upside.

Upcoming Catalysts (preview)

• Q4 2026Announcement of a major pharma partnership for oral GLP-1 agonist program60% success
• H1 2027IND filing for an oral PROTAC candidate40% success
• Q2 2027Series A financing round to fund clinical development70% success